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Summary 
 
Background Psychological treatments for adolescents with unipolar major depressive disorder (MDD) are 
associated with diagnostic remission within 28 weeks in 65%-70% of cases. It is not known however 
whether a particular psychological treatment that is effective for the acute episode results in a sustained 
recovery, thereby reducing relapse risk, in the year following end of treatment.  
Methods In this observer blind, parallel group, pragmatic superiority randomised controlled trial 
(IMPACT), we recruited adolescent patients (11-17 years) with a DSM IV major depressive episode from 
15 NHS CAMHS clinics in England. Participants were randomly assigned to one of two established 
treatments, cognitive behaviour therapy (CBT) or short-term psychoanalytic therapy (STPP), which were 
compared to a reference brief psychological intervention (BPI). Treatment allocation was carried out by the 
trial coordinator using stochastic minimization controlling for age, gender and self-reported depression sum 
score. The patients were followed up and reassessed at five planned time points from randomisation. The 
primary outcome was self-reported depression symptoms obtained at the notional 36,52 and 86 week post 
randomisation assessment. The primary analysis was based on intention to treat. The trial is registered with 
Current Controlled Trials, ISRCTN83033550.  
Findings Between June 29th 2010 and January 17th 2013 we assessed 557 patients of whom 87 were 
excluded as not meeting eligibility criteria, 5 withdrew after treatment allocation and 465 were included. 
These were randomly assigned to BPI (n=155), CBT (n=154) and STPP (n=156) respectively. Treatment 
fidelity and differentiation were established between the three interventions. The median number of 
treatment sessions was significantly different (BPI = 6; CBT = 9, STPP = 11, Kruskal-Wallis rank test 
p<0·001) but there was no difference in the average duration of treatment in weeks between the groups (BPI 
27·5 (sd 21·5), CBT 24·9 (sd17·7), STPP 27·9 (sd16·8), Kruskal Wallis p= 0·238). Of the 465 who entered 
the study 392 (84%) had available data for primary analysis by end of follow up. There were no significant 
differences between STPP and CBT in reducing depressive symptoms by end of study (treatment effect by 
final follow up = 0·578, 95% CI,  -2·948 to 4.104, p= 0·748) nor were there any superiority effects for these 
two treatments (CBT+STPP) compared to BPI (treatment effect by final follow up  = -1·898, 95% CI, -
4·922- 1·126, p= 0·219). By the notional  86 week final assessment there was no significant difference in 
the mean depressive score between treatment groups.  There was an average 49-52% reduction in symptoms 
12 months after the end of therapy. At end of study, 221 (77%) of the 286 consenting to interview, were in 
diagnostic remission. Physical adverse effects (breathing problems, sleep disturbances, drowsiness/tiredness, 
nausea, sweating, restless/overactive) were no different between the groups. Prescribing of an SSRI during 
treatment or in the post treatment follow-up period did not differ between the treatment arms and so did not 
mediate the outcome. The proportion of patients who reported suicide attempts or non suicidal self injury by 
end of study was not increased over the baseline assessments nor associated with SSRI prescribing over the 
study. There were no differences in total costs or quality of life scores between treatment groups. 
Interpretation All three psychological therapies are associated with maintaining reduced depressive 
symptoms up to a year after the end of treatment. STPP is as effective as CBT and together with BPI offers 
additional patient choice for psychological therapy, alongside CBT, for moderately to severely depressed 
adolescents attending routine specialist CAMHS. 
Funding National Institute for Health Research (NIHR) Health Technology Assessment (HTA) programme, 
and the Department of Health. 
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Research in context 
 
Evidence before this study 
Unipolar major depression emerges with the highest incidence risk rate in the second decade of life 
affecting a substantial proportion of the adolescent population worldwide. There is good evidence for 
psychological treatments being associated with clinical remission in some 70% of cases. In contrast data are 
lacking on whether one or more of the available therapies is associated with maintaining reduced depressive 
symptoms a year after the end of treatment. This is a non-trivial issue because lowered depressive 
symptoms below a clinical threshold 12 months after end of treatment is associated with reduced risk for 
diagnostic relapse into the adult years. A literature search was carried out of the USA National Library of 
Medicine (http://www.ncbi.nlm.nih.gov/pubmed/) database from 1st August 1990 to 31st August 2016 using 
the search terms adolescence, depression, psychological treatments, randomised controlled trials, remission, 
relapse, relapse prevention and adverse effects. The search found, 3 trials on school population based 
interventions a small (n=43) feasibility study for a social media intervention for relapse prevention using 
recovered depressed patients and a Cochrane data base review on preventing relapse in depressed children 
and adolescents. Currently there are no identified psychological treatments that can be recommend as 
effective in maintaining reduced depressive symptoms in the year following successful treatment. 
Added value of this study 
This trial showed that there were no superiority effects for either of two established psychological 
treatments, short term psychoanalytic psychotherapy (STPP) and Cognitive Behaviour Therapy (CBT), 
delivered by highly trained therapists over 28 and 20 weeks respectively, against a reference brief 
psychosocial intervention delivered over 12 weeks by child and adolescent psychiatrists and mental health 
nurses. All three psychological treatments were associated with an average 49-52% reduction in depression 
symptoms a year after treatment. Prescribing an SSRI during therapy or follow-up as per NICE guidelines 
did not differ between the treatment arms and so did not mediate the outcome. Suicide attempts and self 
harm attempts over the follow up period were lower than at baseline as were physical  side effects.  
Furthermore there were no differences in total costs or quality of life scores between treatment groups by 
end of study. To our knowledge this is the only high-quality, fully powered superiority and cost-
effectiveness study addressing the medium term effects and costs of psychological treatments on 
maintaining reduced depressive symptoms 12 months after treatment. 
Implications of all the available evidence 
All three treatments are associated with maintaining reduced depressive symptoms up to a year after the end 
of treatment. STPP is as effective as CBT and together with BPI offers an additional patient choice for 
psychological therapy, alongside CBT, for moderately to severely depressed adolescents attending routine 
specialist CAMHS. 
 
Word Count: 4488 
 
 
Introduction 
 
Unipolar major depression (MD) is a significant mental illness affecting a substantial proportion of the 
adolescent population worldwide.1 Although there is evidence for the effectiveness of treatments in the 
short-term, data is lacking on whether one or more of the available psychological treatments is also able to 
maintain reduced depressive symptoms a year after the end of therapy. 2 3 This is a non-trivial issue because 
maintaining lowered depressive symptoms below a clinical threshold level reduces the risk for diagnostic 
relapse into the adult years.4  Cognitive behaviour therapy (CBT) offer plausible long-term benefits for 
depressed adolescents and are recommended as such by NICE.5 Short-term psychoanalytic psychotherapy 
(STPP) alos shows preliminary promise as a therapy for depressed adolescents. CBT has established clinical 
effectiveness and relapse prevention and STPP has evidence for clinical effectiveness in depressed  adults 
comparable to CBT and in adolescents some evidence for clinical effectiveness .6, 7,8,9 In this study we tested 
a primary hypothesis that these two psychological therapies (CBT and STPP) would be significantly more 
likely to maintain reduced depressive symptoms at 86 weeks post randomisation (approximating 52 weeks 
post treatment) when compared to a reference brief psychosocial intervention (BPI). The reference 
intervention has evolved as a manualised form of specialist clinical care (SCC) used as the brief 
psychosocial intervention as usual in a previous trial of depressed adolescents. In that study the findings 
suggested that this intervention maybe clinical effective (see appendix i). 10    
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Method 
Study design and participants 
The “Improving Mood with Psychoanalytic and Cognitive Therapies” (IMPACT) study is a multicentre, 
pragmatic, superiority, parallel, and single blind randomised controlled trial. The study was conducted with 
adolescents with an episode of DSM IV major unipolar depression referred to routine Child and Adolescent 
Mental Health Services (CAMHS) clinics in England.10,11 In the UK National Health Service, adolescents 
who do not respond to community based treatments may be sent to specialist CAMHS outpatients. 
Therefore the depressed adolescents entered into this randomised controlled trial were patients with high 
numbers of symptoms and concurrent personal impairments. The study design and procedures are presented 
in full in the published trial protocol.12 
 
The study was run in three regions of England: East Anglia, a largely rural area of three million people with 
four urban areas each containing approximately 100,000 people; North London, a densely populated urban 
area with around four million people; and the North West of England, covering approximately four million 
people of whom about one million live in rural surroundings and three million living in the City of 
Manchester. There were 15 participating routine CAMHS clinics (five in each region). Patients were 
included from either sex aged 11 through 17 years who met DSM-IV unipolar major depressive disorder 
diagnosis  (MDD). 12 Exclusion criteria were generalised learning difficulties, pervasive developmental 
disorder, pregnancy, currently taking another medication that may interact with an SSRI, current substance 
or alcohol abuse, previously completed one of the study treatments, a primary diagnosis of Bipolar Disorder, 
Schizophrenia or Eating Disorders. No other exclusions were made. The study was approved by the UK 
National Health Service NRES Committee East of England - Cambridge Central  (09/H0308/137) and local 
NHS provider trusts. The trial was conducted and reported in accordance with CONSORT guidelines.13 
 
Randomisation and Masking  
Treatment allocation was carried out by the trial coordinator using stochastic minimization controlling for 
age (11-13;14-15;16-17 years), gender, self-reported depression sum score (< =29; 30-39;40-49; >=50)8 and 
region (East Anglia; North London; North West England)  using an on-line randomization service 
(www.sealedenvelope.com). In view of the nature of the interventions, patients and clinicians were aware of 
treatment allocations. 
 
Measures 
The primary outcome measure was the current level of depressive symptoms as recorded by the self-
reported Mood and Feelings Questionnaire (MFQ). 14 Secondary outcomes were self-reported sum scores on 
the Revised Children’s Manifest Anxiety Scale (RMAS), the revised Leyton Obsessional Inventory (LOI) 
for adolescents, and the Health of the Nation Outcome Scales for Children and Adolescents (HoNOSCA) a 
measure of overall current psychosocial impairment. 15, 16, 17 A brief self-reported antisocial behaviour 
checklist based on DSM IV conduct disorder criteria was used as a binary (none, one or more) measure of 
antisocial behavioural symptoms. The presence of major depressive episode using the Kiddie-Schedule for 
Affective Disorder and Schizophrenia (K-SADS-PL) was also measured over time.18 The study was not 
however powered to test a specific diagnosis hypothesis.  Two additional clinical measures were added: the 
Columbia Suicide Inventory 29; the self-report Risk and Self Harm Inventory. 19 Treatment fidelity and 
differentiation were assessed using the Comparative Psychotherapy Process Scale (CPPS) and (for BPI 
fidelity) the Brief Psychosocial Intervention Scale (BPI-S) (appendix i).21 Economic measures included the 
Child and Adolescent Service Use Schedule (CA-SUS), for collection of service and other resource use, and 
the EQ-5D-3L™ measure of health-related quality of life,  used to calculate quality-adjusted life years 
(QALYs).22,23  
 
 
Procedures 
All treatments were manualised and a description of the treatment manuals including theoretical and 
operational differences, are given in the online appendix (appendix i).   Treatment manuals are also posted 
on a weblink (dev.psychiatry.cam.ac.uk/projects/). A total of 63 therapists delivered BPI, 44 delivered CBT 
and 38 STPP.  Short-term psychoanalytic psychotherapy (STPP) is a 28-session model, with parents or 
carers being offered up to seven additional sessions by a separate parent worker. STPP was a planned 
programme of 28 sessions over 30 weeks. The techniques of STPP are based on close and detailed 
observation of the relationship the child or young person makes with their therapist. The therapist 
introduces the therapeutic task to the young person as one of understanding feelings and difficulties in their 
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life. The therapist is non-judgemental and enquiring and conveys the value of self-understanding. STPP has 
previously been reliably and effectively delivered.9 STPP therapists were CAMHS clinicians with a 
psychoanalytic child and adolescent psychotherapy training. CBT in this trial is based on the classical form 
originally developed for adults with depression .24  It was adapted to include parental involvement, focused 
on engagement in therapy, and highlighted the use of behavioural techniques. The focus of CBT is to 
identify the behaviours and information processing biases that maintain depression and low mood and to 
amend these through a process of collaborative empiricism between the therapist and client. CBT was a 
planned programmer of up to 20 sessions over 30 weeks.  CBT therapists were routine CAMHS clinicians 
and were either clinical psychologists, or other clinicians who had received post qualification training in 
CBT. BPI was formulated and developed from the routine specialist clinical care delivered in the 
Adolescent Depression Antidepressants and Psychotherapy trial (ADAPT).9  The emphasis in the BPI 
programme is on the importance of psychoeducation about depression together with action oriented, goal-
focused and interpersonal activities as therapeutic strategies. Neither self-understanding nor cognition 
change are considered. BPI was derived from a practice based specialist clinical care package used in the 
ADAPT study and reformulated for this investigation based on that trial experience. BPI consists of 12 
individual sessions including up to four family/marital sessions delivered over 20 weeks.  The BPI 
therapists were drawn from routine CAMHS services, the majority (85%, 53) were psychiatrists who had 
passed postgraduate general training (obtained their membership of the Royal College of Psychiatrists) and 
subsequently entered specialist CAMHS psychiatry training as well as consultants.  For all three arms, 
liaison with external agencies and personnel e.g. teachers, social care, and peer group were commonly 
undertaken. All therapy sessions were audiotaped and a random sample of 232 tapes (76 CBT tapes, 81 
STPP tapes and 75 BPI tapes) were selected and rated using the CPPS and the BPI-S rating scales. 
Independent raters rated each treatment session from the three treatment modalities to assess treatment 
fidelity for the CBT, BPI, and STPP arms (Appendix i). Following NICE guidelines fluoxetine could be 
added where clinicians judged that combination therapy may accelerate the time to remission.5 A test dose 
of 10 mg was given for 48 hours followed by 20 mg as a single dose. If there was no improvement within 
two to four weeks the dose could be adjusted upwards to 60 mg maximum. 
 
Study Hypotheses The investigation tested a primary superiority hypothesis that: 
 
i) Compared to patients randomised to BPI, patients who receive either STPP or CBT will be superior at 
maintaining significantly lower self-reported depressive symptoms by end of study. 
 
Since we evaluated two psychological therapies, CBT and STPP, against a reference brief psychosocial 
intervention we first determined if there were differences between them. Therefore we first tested whether 
CBT was inferior to STPP for the same outcomes.  
 
In previous studies of psychological treatment with depressed adolescents, anxiety symptoms have been 
reduced even where depressive symptoms have not. Therefore we tested a secondary hypothesis that: 
 
ii) Compared to those randomised to BPI, patients who received CBT or STPP will be superior at 
maintaining significantly lower self-reported anxiety symptoms but significantly higher research 
interviewer-evaluated psychosocial function by end of study.  
 
Finally a cost-effectiveness hypothesis tested: 
 
iii) Whether the additional cost of the psychological treatments, CBT and STPP, can be justified by 
improvements in clinical effectiveness and/or decreased use of health and social care services compared to 
BPI by 86 weeks follow up.  
 
Sample Size and Statistical Analysis 
A 2.5% two-sided significance level was used for calculating sample size and interpretation of analyses.  
Clustering of patients by therapist was assumed. Five points on the MFQ was taken to represent a clinically 
important difference for assessment of superiority, which corresponds to a one point improvement on five 
of the 33 items of MFQ.  It is a standardize effect size of 0·34 (small to medium) and corresponds to non-
overlap between treatments of approximately 25%. Data from the ADAPT trial gave an estimate of the SD 
of the primary outcome measure (14·6) and correlation between baseline and follow-up (0·41).10 The study 
planned for a recruited sample size of 540. Assuming 90%, (n=486) follow-up and a 2·5% significance 
level to account for multiplicity, the power for the comparison of CBT with STPP was 84% if the ICC was 
zero, 76% for an ICC of 0·025, and 69% if it was as large as 0·05.24 For the comparison of the established 
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treatments (CBT+STPP) with BPI the power was 93%, 88%, and 82% for an ICC of 0·0, 0·025, or 0·05 
respectively. 25 
 
The intention-to-treat principle was applied for all analyses subject to the availability of data. STATA 12.0 
was used for all analyses.  The objective was to establish the outcomes following end of treatment, therefore 
only data from 36, 52 and 86 week assessments were used for the primary analyses.  The marginal treatment 
effect was estimated using a linear mixed model with a random effect for therapist, patient and slope.  To 
prevent bias due to assessments being delayed, time since randomisation was used as a continuous variable 
in a longitudinal mixed model(see appendix ii, section 6.3). MDD diagnoses (present/absent) was analysed 
using a logistic GEE model over the same time period. All analyses included fixed covariates pre-specified 
at baseline  MFQ,  RMAS, LOI,  ABQ scores, treatment allocation, region, sex, age at randomisation, co-
morbid behaviour disorder, prescription of SSRI before trial entry (see statistical analysis plan published in 
appendix iii and https://figshare.com/articles/IMPACT_Statistical_Analysis_Plan/3423109).  
 
Full methods and results of the economic evaluation are reported in the online data (appendix iii) and also 
available on our weblink (dev.psychiatry.cam.ac.uk/projects/). Methods have been applied in a previous 
trial.26 In brief, cost-effectiveness was explored at the 86 week follow up with outcomes expressed as 
quality adjusted life years (QALYs) and costs considered from a service perspective (health, social care, and 
education). Unit costs were for the financial year 2011/12 and costs and QALYs were discounted at a rate of 
3·5% as recommended by NICE.27 Differences in mean costs were tested using linear regression models 
with the validity of the results confirmed using bias-corrected, non-parametric bootstrapping  (5000 re-
samples).25 For the cost-effectiveness analysis, incremental cost-effectiveness ratios (ICERS) were 
calculated (the difference in mean cost divided by the difference in mean effect) and uncertainty was 
explored using cost-effectiveness acceptability curves (CEACs), which show the probability that each of the 
treatments is the optimal choice, for a range of possible values of willingness to pay for additional 
QALYs.28 All economic analyses were adjusted for the pre-specified covariates as well as baseline utility 
and cost, as appropriate. Complete case analysis was used, with the impact of missing data and the impact 
of sessions offered but not attended explored in sensitivity analyses.  
 
Role of the funding source 
The funder of the study had no role in study design, data collection, data analysis, interpretation of data, or 
writing of the paper. The corresponding author had full access to all the data in the study and had final 
responsibility for the decision to submit for publication. 
 
Results 
Between June 29th 2010 and January 17th 2013 we assessed 557 patients from 15 NHS CAMHS teams, five 
from each regional centre in England. Of these 87 were excluded and 470 were recruited (see Figure 1). The 
470 participants were randomised but five withdrew and requested data be deleted (3 BPI, 1 CBT and 1 
STPP). The remaining 465 participants were randomised to BPI (n=155), CBT (n=154), and STPP (n=156), 
respectively. The regional recruitment was: East Anglia 40%, n=185, North West 33%, n=153 and North 
London 27%, n=127. Completed primary outcome measure (MFQ) at each notional time point was: 
baseline 465(100%); 6 week=310 (67%), 12 week= 326 (70%), 36week = 318 (68%), 52 week = 326 (70%), 
86 week = 353 (76%). A total of 392 (392/465, 84%) participants were retained and had data over the 
follow up period and used in the primary analysis (BPI, 132 (85%) of 155, CBT, 133 (86%) of 154, STPP, 
127 (81%) of 156). Of these 39 (10.0%) had one, 90 (23.0%) and 263 (67%) had 3 MFQ scores. The pattern 
of collected secondary outcomes was similar between treatment groups. The data available was within the 
margins suggested by the power calculation. Baseline characteristics were balanced between treatment 
groups (see Table 1). There were no significant differences between treatment groups. 
 
 
Figure 1 about here 
Table 1 about here 
 
The full depression symptom profile at baseline is shown in appendix 2 (table A1). The mean number of 
symptoms was: BPI= 8·4, CBT=8·7,  STPP= 8·3. The most prevalent symptom was sleep disturbance (92%, 
427) followed by depressed mood (84%, 390). Psychotic symptoms were uncommon (10%, 48) but current 
suicidal ideas (61%, 284) and lifetime suicide attempts were notable (38%, 177).  There were no symptom 
prevalence differences between the treatment groups. A total of 225 (48%) were concurrently comorbid 
with 71(46%,) for BPI, 80(52%) for CBT and 73(47%) for STPP groups(appendix 2, table A2). Overall 134 
(29%) reported one, 60 (13%) two and 31(7%) 3 or more non-depressive comorbidities with no marked 
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differences between the groups. Non-suicidal self injury (NSSI) in the last 2 weeks was reported by 85 
(18·3%) of the patients: BPI = 26, (17%), CBT= 25 (16%), STPP= 34 (22%).  Lifetime NSSI was reported 
by 246 (53%) participants: BPI= 87 (56%), CBT= 75 (49%), STPP= 84 (54%). 
 
Uptake and duration of trial therapies 
The numbers of patients who started therapy were: BPI= 138 of 155 (89%), CBT= 133 of 154 (86%), 
STPP=133 of 156 (85%)  (appendix, table A3). The proportion that initiated treatment did not differ by arm 
(𝜒2
2p=0·203). The number of individual treatment sessions given per group was briefer than planned but 
significantly different: (median) BPI= 6, CBT= 9, STPP= 11 (Kruskal-Wallis rank test p<0.001). Of those 
patients randomised to BPI 24 , (17%) had more sessions than the manual specified, compared to  5 (3%) 
for CBT and 3 ( 2% ) for STPP. Average duration of therapy between treatment groups was not 
significantly different: BPI 27·5 (sd 21·5), CBT 24·9 (sd17·7) and STPP 27·9 (sd16·8) weeks (Kruskal 
Wallis p= 0·238).  
 
Treatment fidelity and differentiation 
Overall 81% of BPI , 80% of STPP and 74% of CBT sessions met criteria. Treatment differentiation was 
good: the mean cognitive-behavioural (CB) sub-scale score on the CPPS was 1·91 higher for CBT than 
STPP sessions (95% CI 1·73 to 2·09,p <0·0001). The mean psychodynamic-interpersonal (PI) sub-scale 
score on the CPPS was 1·18 higher for STPP than CBT sessions (95% CI 1·01 to 1·3, p <0·0001). BPI 
sessions had a significantly lower CB sub-scale mean than CBT (mean diff. = -0·93, 95% CI -1·12 to -0·75, 
p<0·0001) and a significantly lower PI sub-scale mean than STPP (mean diff. =-1·30, 95% CI -1·48 to -
1·11, p<0·0001). 
 
Medication 
We noted that 89 (19%) patients were receiving an SSRI prior to randomisation: BPI= 29 (19%), CBT= 32 
(21%), STPP= 28 (18%) . By the end of study the proportion of patients in each arm who reported having 
received an SSRI at any time over the course of the trial (randomisation through to 86 weeks) per treatment 
group were: 56 (41%) for BPI, 55 (40%) for CBT, and 50 (36%) for STPP (𝜒2
2 𝑝=0.729) (appendix ii table 
A4). 
. 
Clinical results 
Table 2 gives summary statistics and the treatment effect estimates from the Linear Mixed Model. To 
investigate non-response a logistic GEE model was fitted to an indicator variable for missing primary 
outcome data. Behavioural disorder at baseline was found to predict non-response. As this was not a pre-
specified baseline covariates it was added to all models of outcome to support the missing at random 
assumption. Time from randomisation to assessment and estimates of the main effect and time with 
treatment interaction are given in appendix ii table A5 and A6 respectively. 
  
Table 2 about here 
 
For the primary outcome at end of study there were no significant differences between STPP and CBT and 
none for combined treatments (CBT+STPP) compared to BPI. With a lower score representing improved 
outcome there was a larger difference in favour of combined established treatments of -3·234 (95% C.I. -
6.611 to 0.143) at 36 week and -2·806 (-5.790 to 0.177) at 52 week assessments but these reductions were 
not statistically significant, less than the five units pre-specified as a clinically meaningful difference and 
not accompanied by differences in psychosocial impairment. The secondary outcomes revealed a significant 
reduction in anxiety and obsessional symptoms for the established therapies as compared to reference 
therapy at 36 week only. The intra-cluster correlation coefficient (ICC) for therapist was calculated as the 
proportion of the random intercept variance and was negligible (<10-7) for all of the models. Study power 
was therefore at the upper end of the range as the sample size calculation considered a range of values of the 
ICC from 0 to 0.05.   
 
The two secondary binary outcomes were the proportion of patients who i) self reported none or one or 
more antisocial behaviour symptoms ii) met clinical diagnostic criteria for MDD. The prevalence at each 
assessment point for both is shown in table 3. 
 
Table 3 about here 
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Compared to BPI, the proportion of patients receiving an established psychological treatment  
(CBT+STPP) had significantly lower self reported ASB at 36 week assessment (Adj. diff -12.8% , 95% 
c.i. -23.8% to -1.9% ,p=0.022) but no significant difference by end of study (p=0.389).  
 
There were no significant group differences for the proportion of patients in diagnostic remission by 36, 52 
or 86 weeks. As this is a pragmatic study with no control group we compared the proportion in remission at 
12 weeks with the proportion of remitted patients from the published TADS study randomised to a pill 
placebo control group (n=111) and also assessed at 12 weeks which gave: 145 (48%) of 305 patients 
compared to 37 (34%) of 111 pill placebo patients. 3 Additionally the treatment trial of resistant depression 
in adolescents, reported 61% in diagnostic remission by 72 weeks compared with 78% by the 86 week 
follow up in this study.29  Finally15 (11%) patients relapsed by end of study from the 140 in remission at 36 
and reassessed at 86 weeks (BPI= 5(11.6%)/48, CBT= 4(16.5%)/49, STPP 2 (4%)/48 STPP, p=0.149). 
Caution is required with these results: the study was not powered for treatment group comparisons, there are 
missing interview data at each time point and the control comparison could only be achieved at 12 weeks.     
 
Suicide Attempts and non-suicidal self injury  
Over the follow up period the proportion of patients who reported recent suicide attempts at each re-
assessment point were: 36 week = 3 (3%)/279, 52 week = 2 (6%) /201, 86 week = 0/205 compared to 12 
(3%)/465 at baseline. Similarly NSSI attempts were: 36 week = 19(7%)/268; 52 week= 14(4%)/234; 86 
week= 16(5%)/257 which compares favourably with baseline = 85 (18%)/465 patients. 
 
Adverse effects of treatment 
There are no standardised methods for measuring the adverse effects of psychological treatments given to 
depressed adolescents. We derived a physical adversities score from self-reported items of breathing 
problems, sleep disturbances, drowsiness/tiredness, nausea, sweating, and being restless/overactive rated 
present/absent. Results are shown in table 4: there is a decline in the self reporting of adverse physical 
events over the course of the study with no observable differences between treatment groups.  
 
Cost-Effectiveness 
The cost of the trial interventions was: CBT (£904·57), BPI (£1292·91) and STPP (£1396·72). Use of all 
other services by 86-weeks differed little between groups: total costs =   BPI (£1368·04), CBT ( £1459·26) 
STPP (£1668·51) (see appendix ii & iii). Including the cost of the trial interventions increased total costs 
per participant: BPI (£2678·39), CBT (£2379·01), STPP (£3081·70) respectively. There were no significant 
differences in these costs between treatment groups and no significant differences in QALYs (BPI group 
1·241, CBT group 1·228 and STPP 1·246 QALYS over the 86 week follow up). There is no evidence to 
support the superior cost-effectiveness of STPP compared to BPI or CBT, nor of CBT compared to BPI (see 
appendix ii &iii for details). 
Discussion 
This trial found no evidence for the superiority of Cognitive Behaviour Therapy (CBT) or Short Term 
Psychoanalytic Therapy (STPP), compared to a brief psychosocial intervention (BPI), for maintaining 
reduced depression symptoms by end of study.  This is the first trial to show that STPP and BPI are as 
clinically effective as CBT for the treatment of adolescent depression. We note the continuing decline of 
symptoms and further increase in remission, which are not explained by any marked differences in post-
treatment service use, costs between therapies or reported SSRI use. We also note that there was a small 
reduction in symptoms in favour of established treatments at the end (36 weeks) of treatment but not by end 
of study, which is consistent with prior reports of psychological treatment effects on reducing anxiety in 
depressed patients.30 There was no increase in suicidality, non-suicidal self-injury or adverse physical side 
effects in any therapy group over the study.  
 
Three previous randomised controlled trials similar in design report follow up data beyond end of treatment. 
Birmaher and colleagues reassessed 107 adolescents with MDD two years after being treated with cognitive 
behavioral therapy, systemic behavioral family therapy, or nondirective supportive therapy. They reported 
no differences in outcome by original treatment group.31 A naturalistic follow up study of 190 (44·6%, 89 of 
the original sample) depressed adolescents recruited to a treatment trial reported that five years post- trial 
recurrence was more likely in those with higher depressive symptoms at the end of treatment but was not 
associated with treatment type. 32 Most recently a 6 year follow up of a cognitive behaviour programme 
(CBP) aimed at preventing depressive episodes noted the strongest effect was early and maintained better 
with additional booster sessions and treatment of parental depression. 33 Overall these findings are 
consistent with suggesting early response to treatment can be followed by continued improvement across 
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different treatment modalities.  The lack of difference between these three treatments suggests there may be 
due to a putative shared common effect but there are alternative explanations including 3 unique effects 
leading to the same outcome and even no effect with the decline in symptoms being due to change over time. 
 
There are also reports of non-response to treatment in 21-25% of trial patients consistent with these results. 
3,10,29,30,31 This may be an issue of selecting the right treatment for the right patient, noting the likelihood of 
resistance to a given treatment early in therapy, or predicting the likelihood of non-compliance. One 
challenge for further research is to improve the precision of our ability to select the best therapy for a given 
depressed adolescent from the available treatment options.  Despite the planned differences in treatment 
intensity, in practice young people attended a median of six to eleven sessions over 25-28 weeks across all 
three treatment arms. A first course of therapy for depressed adolescents could be brief (6-11 sessions) and 
at no difference in cost between the available treatment options evaluated in this trial.  The reasons for non-
attendance deserve further investigation.  
This study had many strengths including that participants were representative of moderate to severe 
depression with self-harm, suicidality, and non depressive comorbid disorders at point of referral, referred 
to CAMHS across diverse regions of the UK, all met research diagnostic criteria for DSM IV Major 
Depressive Disorder, randomised remotely from the research team. There was a loss to follow up but the 
primary outcome measure (MFQ) was available in 84% of those randomised over the follow up period. The 
overall sample size was greater than prior studies and this is the first time a trial of depressed adolescents 
has designed to follow-up  for 52 weeks after end of treatment.  Each of the three treatments was 
manualised, therapies were delivered as expected and clear differences in approach were maintained 
between them.  Some patients in all three groups received antidepressant medication. This characteristic 
strengthens generalisability but limits the interpretation of the findings. There were no prescribing 
difference between arms over the study and fluoxetine was prescribed both during and after the end of 
treatment. Neither the reasons for prescribing nor medication compliance were controlled for over the study 
course. We cannot therefore exclude the possibility that SSRIs may have contributed to the improvements 
over time. Furthermore the observed declines in symptoms and improvements in well-being could be a 
function of time. The absence of a no treatment control group limits the assertion that any therapy was 
causally effective. The economic results were limited by missing data, which was higher than for the 
primary clinical outcome measure (40%). Multiple imputation of missing data did not however change the 
economic results of the analysis. Future research should focus on psychological mechanisms associated 
with: treatment response, the maintenance of positive effects, non-response, and whether or not brief 
psychotherapies are of utility in community and primary care settings.  
We conclude that all three treatments are associated with maintenance of reduced depressive symptoms a 
year after the end of treatment. STPP and BPI offers additional patient choice, alongside CBT for depressed 
adolescents attending routine specialist CAMHS.  
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Figure 1 
 
 
 
 
The primary hypothesis was analysed with 392 (84%), of 465 who were randomised, accepted treatment and provided one or more self 
reported depression symptom score over the 36,52 or 86 week notional assessment points. Of these 39 (10%) had just one, 90 (23.0%) 
had two and 269 (67%) all three assessments scheduled.   
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Table 1: Characteristics of participants at baseline 
 
 BPI 
(N=155) 
CBT 
(N=154) 
STPP 
(N=156) 
Demographics    
Mean Age in Years (range)   15 (11-17) 15 (12-17) 15 (11-17) 
Females 115 (74%) 114 (74%) 119 (76%) 
White* 121 (82%) 131 (86%) 130 (86%) 
Stratification Variables     
    East Anglia 61 (39%) 62 (40%) 62 (40%) 
    North London 43 (28%) 41 (27%) 43 (27%) 
    North West 51 (33%) 51 (33%) 51 (33%) 
Conduct/Oppositional Disorder 20 (13%) 20 (13%) 16 (10%) 
Mean (SD) self-reported depression  
score  
46·2 (10·6) 46·2 (10·3) 45·4(10·8) 
 
Psychiatric Characteristics at 
Randomisation 
   
Mean number of Interviewer 
assessed depressive symptoms  8·4 (2·5) 8·7 (2·3)  8·3 (2·5)  
SSRI prescribed before trial entry + 29 (19%) 32 (21%) 28 (18%) 
Prevalence of 1 or more comorbid 
DSM-V axis 1 psychiatric diagnoses 
71(46%) 80(52%) 74 (47%) 
One or more Recent Suicide 
Attempts^ 
3 (2%) 2(1%) 7 (5%) 
Lifetime Suicide Attempts 57 (37%) 48(31%) 55 (35%) 
Recent Self Harm Attempts^ 26 (17%) 25(16%) 34 (22%) 
One Or More Lifetime Non Suicidal 
Self Injury Episodes 
87 (56%) 75(49%) 84  (54%) 
Quality of Life at Randomisation     
Mean (sd) HoNOSCA scores 18·9 (6·0) 18·4(6·0) 18·3 (6·3) 
Mean (sd) EQ5D scores 0·596 (0·27) 0·578 (0·58) 0·569 (0·59) 
*excludes n=15 where ethnic group/origin was not stated or missing 
+excludes n=9 with missing information 
^ last 2 weeks
  12 
 
  
Table 2: Mean outcome by treatment group over the trial for primary outcome and secondary outcomes 
Assessment BPI CBT STPP Hypoth. Weeks Treatment (95% C.I.) p-valueb 
 
Mean SD n Mean SD n Mean SD n 
  
Effecta 
  
Primary 
              
MFQa 
              
Baseline 46.2 10.6 155 46.2 10.3 154 45.4 10.8 156 STPP  36 0.179 (-3.731 to 4.088) 0.929 
6 week 36.5 14.3 99 35.2 11.3 104 34.9 13.2 107 vs. CBT 52 0.307 ( -3.161  to 3.774) 0.862 
12 week 34.1 14.4 112 31.6 13.3 106 33.1 14.2 108   86 0.578 ( -2.948  to 4.104) 0.748 
36 week 30.5 16.1 105 24.2 15.1 104 26.6 15.7 109 (CBT+STPP)  36 -3.234 (-6.611 to 0.143) 0.061 
52 week 25.1 16.2 105 25 18.0 111 23.0 15.9 110 vs BPI 52 -2.806 (-5.790 to 0.177) 0.065 
86 week 23.6 16.2 116 22.3 15.7 123 21.8 15.5 114   86 -1.898 (-4.922 to 1.126) 0.219 
Secondary 
              
RCMASa 
              
Baseline 41.1 7.6 155 41.2 6.4 154 40.5 7.7 155 STPP  36 0.855 (-2.530 to 4.239) 0.621 
6 week 35.9 10.6 98 37.1 7.9 103 36.7 10 107 vs. CBT 52 0.663 (-2.354 to 3.680) 0.667 
12 week 34.2 11.9 110 34.4 11.4 105 34.3 11.9 108   86 0.254 (-2.980 to 3.489) 0.878 
36 week 32 13.3 104 27 13.7 102 28.6 13.3 107 (CBT+STPP)  36 -3.832 (-6.781 to -0.884) 0.011 
52 week 27.2 14.8 100 26.4 14.9 108 25.5 14.5 104 vs BPI 52 -2.818 (-5.432 to -0.205) 0.035 
86 week 24.7 14.7 109 24.8 15.4 115 23.8 14.6 108   86 -0.663 (-3.460 to 2.134) 0.642 
LOIa               
Baseline 10.0 5.3 155 10.8 5.4 152 9.2 5.0 154 CBT vs STPP  36 -0.816 (-1.972 to 0.341) 0.167 
6 weeks 7.8 5.4 98 7.6 5.0 102 7.6 5.0 107   52 -0.574 (-1.601 to 0.452) 0.273 
12 weeks 6.6 5.6 111 6.7 5.2 104 7.3 5.1 107   86 -0.062 (-1.091 to 0.967) 0.906 
36 weeks 6.3 5.4 103 4.8 4.8 101 5.2 4.9 107       
52 weeks 
5.6 5.8 99 5.1 5.5 107 4.9 4.7 102 
(CBT+STPP)  
vs BPI 
36 -1.249 (-2.258 to -0.240) 0.015 
86weeks 5.0 5.4 107 4.9 5.0 115 4.0 4.6 106   52 -1.120 (-2.010 to -0.231) 0.014 
           86 -0.847 (-1.736 to  0 .042) 0.062 
HoNOSCAa 
              
Baseline 18.9 6.0 148 18.4 6 143 18.2 6.3 144 STPP  36 0.617 (-1.499 to 2.733) 0.567 
6 week 14.5 6.5 88 14.1 6.4 91 14.6 6.9 96 vs. CBT 52 0.620 (-1.078 to 2.318) 0.474 
12 week 14.3 7.5 101 11.9 6.8 96 12.9 6.2 94   86 0.626 (-0.814 to 2.066) 0.394 
36 week 12 8.7 88 9.7 7.2 81 10.3 7.6 88 (CBT+STPP)  36 -1.410 (-3.221 to 0.401) 0.127 
52 week 9.5 6.9 88 8.5 7.3 86 8.6 5.8 83 vs BPI 52 -1.154 (-2.601 to 0.293) 0.118 
86 week 8.2 6.2 98 7.3 5.2 92 8.2 7.2 85   86 -0.611 (-1.819 to 0.598) 0.322 
a Linear Mixed Model estimates of the treatment effect at 36, 52, and 86 week post randomisation. Model based on data from 
392 (84%), of 465 patients who provided one or more self reported depression symptom score over the 36,52 or 86 week notional 
assessment points. The analysis used time since randomisation as a continuous variable with therapist, participant and slope 
random effects, treatment, treatment by time interaction, and other pre-specified baseline covariates (see appendix). 
Treatment effect is the marginal mean difference at time point with negative effects indicating treatment benefit.  
Missing MFQ data at each assessment by group: 36 week, BPI 32%, 50 ; CBT 32%, 50 ; STPP 30%, 47 ;  52 week, BPI 32%, 50; CBT 
28%, 43 ; STPP 29%, 46; 86 week  25%, 39 ;  CBT 20%, 31 ; STPP 27%, 42. 
MFQ: Mood and Feelings Questionnaire; RCMAS: Revised Children’s Manifest Anxiety Scale; LOI: Leyton Obsessional 
Inventory-Adolescent version HoNOSCA: Health of the Nation Outcome Scale for Children and Participants 
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Table 3: Proportion of Patients with MDD Diagnosis and One or more Antisocial Behaviour Symptoms (ABQ) 
Assessment BPI (N=155) CBT (N=154) STPP (N=156) *Hypoth. Weeks Treatment (95% C.I.) p-valueb 
 
N Total (%) N Total (%) N Total (%) 
  
Effecta 
  
MDD+ 
              
Baseline 155 155 (100) 154 154 (100) 156 156 (100) STPP  36 -0.064 (-0.206 to 0.078) 0.375 
6 week 63 143 (99) 57 95 (60) 62 99 (63) vs. CBT 52 -0.018 (-0.120 to 0.084) 0.727 
12 week 57 105 (54) 46 98 (47) 54 99 (54)   86  0.057 (-0.043 to 0.157) 0.261 
36 week 42 95 (44) 28 89 (31) 35 98 (36) (CBT+STPP)  36 -0.043 (-0.160 to 0.073) 0.465 
52 week 27 92 (29) 23 90 (26) 23 87 (26) vs BPI 52 -0.053 (-0.142 to 0.035) 0.239 
86 week 27 99 (27) 24 95 (25) 14 92 (15)   86 -0.065 (-0.152 to 0.022) 0.145 
               
ABQ 
              
Baseline 121 155 (78) 124 152 (81.6) 128 154 (83.1) STPP  36 -0.068 (-0.186 to 0.051)) 0.263 
6 week 75 98 (76) 71 102 (69.6) 73 107 (68.2) vs. CBT 52 -0.040 (-0.135 to 0.055) 0.408 
12 week 78 111 (70) 57 104 (54.8) 52 107 (48.6)   86 0.018 (-0.083 to 0.120) 0.725 
36 week 62 103 (60.2) 45 101 (44.6) 55 107 (51.4) (CBT+STPP)  36 -0.128 (-0.238 to -0.019) 0.022 
52 week 47 99 (47.5) 43 107 (40.2) 41 102 (40.2) vs BPI 52 -0.074 (-0.163 to 0.015) 0.102 
86 week 39 107 (36.4) 49 115 (42.6) 43 106 (40.6)   86 0.040 (-0.051 to 0.131) 0.389 
 
*Logistic GEE of the treatment effect at 36, 52, and 86 weeks post randomisation. Model based on data from 36 weeks post-randomisation with therapist, participant and slope random effects, treatment, 
treatment by time interaction, and other pre-specified baseline covariates ( or SAP. Treatment effect is the marginal mean difference at time point with negative effects indicating treatment benefit.  
+This study was not powered to  test for treatment differences in clinical diagnostic relapse and these results must be viewed with caution.. 
MDD: Major Depressive Disorder ; ABQ: Antisocial Behaviour Questionnaire.   
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Table  4: Summary statistics for adverse event score based on 6 adverse event items at each  assessment  
A
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STPP*  
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M
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M
ed
 
M
in
 
M
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Baseline 155 5.0 1.1 5 1 6 154 5.1 1.0 5 2 6 156 5.0 1.1 5 2 6 
6 weeks 99 4.4 1.5 5 0 6 104 4.6 1.3 5 2 6 107 4.4 1.5 5 0 6 
12 weeks 112 4.2 1.6 4 0 6 106 4.0 1.5 4 0 6 108 4.2 1.6 4 0 6 
36 weeks 105 4.1 1.6 4 0 6 104 3.6 1.6 4 0 6 109 3.6 1.7 4 0 6 
52 weeks 105 3.5 1.8 3.5 0 6 111 3.5 1.9 4 0 6 110 3.2 1.9 3 0 6 
86 weeks 116 3.3 1.8 3.5 0 6 123 3.4 1.9 4 0 6 114 3.2 1.8 3 0 6 
 
* Sample size at each time point varies  and is given in detail in table 3 above. The total sample size for each notional assessment period was baseline 465(100%); 6 week=310,67%,12 week= 326,70%, 36week = 
318,68%, 52 week =  326, 70%, 86 week = 353, 76%. table  
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